EQ

Equillium, Inc.
CAPPED RATING

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium, Inc. (EQ) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.5 / 5.0
Profitability
D
Factor Score 1.5 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.1
EV / EBITDA -1.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -33.0%
Price Return 12M 32.7%
Catalyst Signal 0.00
Market Cap $114.0M
TTM Revenue N/A
Price / Sales N/A
ROE -59.0%

Historical Factor Score Progression

Held C- for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D+ (1.5) D (1.5) C- (2.0) C+ (2.6) C- (2.0)
2026-11-04 C+ (2.5) D+ (1.5) D+ (1.5) D+ (1.8) C+ (2.7) C- (2.0)
2026-10-28 C+ (2.5) D+ (1.5) D+ (1.5) C- (1.9) C+ (2.7) C- (2.0)
2026-10-21 C+ (2.5) D+ (1.5) D+ (1.5) C- (1.9) C+ (2.6) C- (2.0)
2026-10-14 C+ (2.5) D+ (1.5) D+ (1.5) C (2.4) C+ (2.6) C- (2.1)
Page 1 of 6